Paper Details

  1. Home
  2. Paper Details

Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study.

Author: AusinPilar, BjermerLeif, CarlssonLars-Goran, CazzolaMario, EkelundJan, LotvallJan, PaggiaroPierluigi, PalangePaolo

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Formoterol 9 μg has a more rapid onset of bronchodilatory effect than salmeterol 50 μg in patients with moderate chronic obstructive pulmonary disease (COPD), as measured by FEV1 at 5 minutes post-dose.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Bronchodilator therapy is central to the symptomatic management of chronic obstructive pulmonary disease (COPD), and treatment with short-acting bronchodilators is recommended in patients with mild COPD. OBJECTIVE: This study aimed to evaluate the onset of effect of single-dose formoter...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2165/11630880-000000000-00000

データ提供：米国国立医学図書館（NLM）

Formoterol: A Faster Relief for Moderate COPD

Chronic obstructive pulmonary disease (COPD) is a challenging condition, often requiring ongoing management to improve lung function and quality of life. This study, published in the field of COPD, investigates the onset of action of two long-acting bronchodilators, formoterol and salmeterol, in patients with moderate COPD. The researchers conducted a randomized, placebo-controlled, double-blind, crossover study to compare the speed of bronchodilation achieved with formoterol and salmeterol, measured by changes in forced expiratory volume in 1 second (FEV1) at 5 minutes after inhalation.

Formoterol: A Faster Relief for Moderate COPD

The study's findings demonstrate that formoterol has a more rapid onset of action than salmeterol in patients with moderate COPD. Formoterol produced a significantly greater increase in FEV1 at 5 minutes after inhalation compared to salmeterol. This finding suggests that formoterol may offer a faster and more effective relief for individuals with moderate COPD.

Navigating the Desert of COPD: Finding the Right Bronchodilator

The study's findings offer valuable insights into the benefits of formoterol for patients with moderate COPD. The faster onset of action of formoterol could be particularly beneficial for individuals experiencing acute exacerbations of COPD, providing quicker relief and potentially improving symptom control. As always, consulting with a qualified healthcare professional is essential for determining the best treatment option for each individual.

Dr. Camel's Conclusion

This study, like a refreshing oasis in the vast desert of COPD research, reveals that formoterol offers a faster onset of action than salmeterol, potentially providing quicker relief for individuals with moderate COPD. The researchers' findings highlight the importance of carefully considering the speed of bronchodilation when selecting a long-acting bronchodilator for COPD patients.

Date :
  1. Date Completed 2012-06-15
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

22235841

DOI: Digital Object Identifier

10.2165/11630880-000000000-00000

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.